22. もやもや病 Disease details / Clinical trials / Drug dev / DR info

臨床試験数 : 23 / 薬物数 : 29 - (DrugBank : 21) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 50

薬物、開発者（Primary Sponsor）、臨床試験情報（症例登録開始年（Enrollment year）、フェーズ、ID、実施国）
ANI (analgesia/nociception index) monitoring
   Seoul National University Hospital
      2023   -   NCT05672212   Korea, Republic of
Aspirin
   Beijing Tiantan Hospital, Capital Medical University
      2019   -   ChiCTR1800020377   China
   Capital Medical University
      2019   -   NCT04012268   China
   Qilu Hospital of Shandong University
      2021   -   ChiCTR2100046178   china
Atorvastatin
   Department of Neurosurgery, PLA General Hospital
      2022   Phase 4   ChiCTR2200064976   China
Butylphthalide
   yuanli Zhao
      2020   Phase 3   NCT04205578   China
Desflurane
   The First Affiliated Hospital of Zhengzhou University
      2019   Phase 4   ChiCTR1900027197   China
Dexmedetomidine
   Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School
      2024   -   ChiCTR2400082013   China
Edaravone
   Department of Neurosurgery, Hokkaido University Graduate School of Medicine
      2012   -   JPRN-UMIN000008742   Japan
Erythropoietin
   Ajou University School of Medicine
      2010   Phase 1/Phase 2   NCT03162588   Korea, Republic of
   Seoul National University Hospital
      2019   -   NCT03882060   Korea, Republic of
Fluorescein
   Akiyama Hideo
      2021   -   JPRN-jRCTs031200402   -
G-CSF
   Morioka Motohiro
      2022   Phase 1-2   JPRN-jRCTs071220048   -
Gadobutrol
   Aoki Shigeki
      2018   -   JPRN-jRCTs031180017   -
Indocyanine green
   Akiyama Hideo
      2021   -   JPRN-jRCTs031200402   -
Lidocaine
   the First Affiliated Hospital of Sun Yat-Sen University
      2021   Phase 0   ChiCTR2100050015   China
Magnetic resonance imaging
   Stanford University
      2009   -   NCT01419275   United States
Norepinephrine
   The South District of Anhui Provincial Hospital
      2021   Phase 4   ChiCTR2000041260   China
      2020   Phase 4   ChiCTR2000029878   China
Normal saline
   Seoul National University Hospital
      2019   -   NCT03882060   Korea, Republic of
Normal saline 0.9% infusion solution
   yuanli Zhao
      2020   Phase 3   NCT04205578   China
Oxygen
   Peking University International Hospital
      2023   Phase 1   ChiCTR2300075268   China
Phenylephrine
   The South District of Anhui Provincial Hospital
      2021   Phase 4   ChiCTR2000041260   China
      2020   Phase 4   ChiCTR2000029878   China
Propofol
   Peking University International Hospital
      2023   Phase 1   ChiCTR2300075268   China
   The First Affiliated Hospital of Zhengzhou University
      2019   Phase 4   ChiCTR1900027197   China
   the First Affiliated Hospital of University of Science and Technology of China
      2024   Phase 0   ChiCTR2400087467   China
Remifentanil
   Peking University International Hospital
      2023   Phase 1   ChiCTR2300075268   China
   the First Affiliated Hospital of University of Science and Technology of China
      2024   Phase 0   ChiCTR2400087467   China
Revascularization/conservative management
   Beijing Tiantan Hospital
      2024   -   NCT06817434   China
RIC
   Capital Medical University
      2019   -   NCT04012268   China
Ropivacaine
   The First Affiliated Hospital of Sun Yat-sen University
      2021   Phase 1   ChiCTR2100050185   China
Sevoflurane
   Peking University International Hospital
      2023   Phase 1   ChiCTR2300075268   China
   Seoul National University Hospital
      2015   -   NCT02510586   -
   the First Affiliated Hospital of University of Science and Technology of China
      2024   Phase 0   ChiCTR2400087467   China
Standard monitoring
   Seoul National University Hospital
      2023   -   NCT05672212   Korea, Republic of
Sufentanil
   Seoul National University Hospital
      2023   -   NCT05672212   Korea, Republic of
Water
   Akiyama Hideo
      2021   -   JPRN-jRCTs031200402   -
Xenon contrast agent
   Stanford University
      2009   -   NCT01419275   United States